BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Search
Boehringer Ingelheim Office Hours Video 2023
Boehringer Ingelheim’s Office Hours program provides mentoring and access to expertise to help early-stage companies advance their science.
About Boehringer Ingelheim Partnering Days
Find out more about our partnering days and how we can work together to accelerate your science
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim
Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
European Metacam® indication expanded to guinea pigs
Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Ranking in the top 25% in EcoVadis Sustainability Assessment
Boehringer Ingelheim has received a silver medal from EcoVadis in the 2023 sustainability assessment, including above industry average scores.
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
LastMile initiative to address barriers in animal healthcare
The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
Aseptic filling services | Bioxcellence | Boehringer Ingelheim
Discover top-notch aseptic processing for biopharmaceuticals with our filling services, specializing in freeze-dried products & liquids.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Animal Health Collaboration with Novozymes
Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care